Skip to content

EV / sales at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
14×+10.9×
ALN
Alnylam PharmaceuticalsALNY
9.9×-4.7×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-127.1×-128×
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
4.5×-94.3×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
19×-10.6×
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
2.5×+1.1×

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×
Current ratio6.6×+4.6×

Where this comes from

Calculated from Assembly Biosciences’s reported figures.

Based on the most recent quarter.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's EV / sales?
Assembly Biosciences (ASMB) reported EV / sales of 5.8× in Q1 2026.
How has Assembly Biosciences's EV / sales changed year-over-year?
Assembly Biosciences's EV / sales increased by 262.5% year-over-year, from 1.6× to 5.8×.
What is the long-term trend for Assembly Biosciences's EV / sales?
Over 3 years (2020 to 2025), Assembly Biosciences's EV / sales has grown at a 30.0% compound annual growth rate (CAGR), from 3× to 6.7×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.